| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
A new study by Quest Diagnostics has ranked Georgia third in the nation for the most increases in Lyme disease between 2015 and 2017.
here's been a sharp spike in Lyme disease cases in the United States, and the tick-borne illness has now spread to all 50 states, a new report shows. "Lyme disease is a bigger risk to more people in the United States than ever before," said Dr. Harvey Kaufman, senior medical director for Quest Diagnostics, which conducted the study.
Blockchain is here to stay. Here is what we need to do to make it better.
Last month’s Alzheimer’s Association International Conference (AAIC) 2018 heralded many announcements, including the mixed reception around Phase II trials results from Biogen’s Alzheimer’s drug BAN2401. Like many treatments in AD, it addressed build up of amyloid plaques in the brain. However, many drug failures in that area, as well as Pfizer’s exodus from Alzheimer’s and Parkinson’s research early this year, has led to investors and scientists to reevaluate the plaque theory. Edward I. Ginns, MD, PhD, medical director, neurology, for Quest Diagnostics, said, “When we see patients at the point of clinical identification, the brain is pretty much out of resources. It’s unlikely that neurons that are dead or non-functional will be treated at that late stage.” To that end, Quest Diagnostics wanted to identify patients with cognition problems earlier. They developed CogniSense, a cognition test that is available as an app for the iPad and given in the primary care doctor’s office.